Skip to main content
. Author manuscript; available in PMC: 2019 Oct 14.
Published in final edited form as: Vasc Med. 2019 Jul 5;24(5):414–421. doi: 10.1177/1358863X19859072

Figure 4.

Figure 4.

Sensitivity analysis (LOCF) supports improvement in PFWD with canakinumab treatment. LC means (80% CI) of placebo-adjusted change from baseline in maximum 6MWT distance are presented with the LOCF for any missing data.

*p < 0.05 versus placebo.

LC, least-squares; LOCF, last observation carried forward; PFWD, pain-free walking distance; 6MWT, 6-minute walk test.